Aptamer Advantage Position Base Pair Biotechnologies as a specialized provider of rapid aptamer discovery with a patented multiplexed approach, highlighting advantages over traditional antibodies to attract biotech groups seeking alternative affinity ligands.

Canine Oncology Focus Leverage recent NIH SBIR-funded work on canine oncology biomarkers to pursue partnerships with veterinary diagnostic labs, pet health researchers, and comparative oncology initiatives seeking aptamer-based assays.

Early Stage Growth Target the small team setup (2-10 employees) as a lean, agile partner for collaborations, contract research, or pilot projects, offering flexible engagement models and rapid turnaround for proof-of-concept studies.

Buffer and Reagent Portfolio Highlight the availability of ready-to-use Aptamer Resuspension, Folding, and Reducing Buffers as value-added products to upsell to current and prospective customers running aptamer workflows.

Strategic Fit with CROs Position the company as a complementary capability for larger CROs and biotech firms lacking aptamer discovery speed, with potential for co-development, licensing, or subcontracted discovery work to scale their affinity ligand pipelines.